Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. Department of Energy

Latest From U.S. Department of Energy

Hopes For Disease Modification In Huntington’s Disease

A group at the Lawrence Berkeley National Laboratory believes that a synthetic antioxidant previously shown to reduce apoptosis and enhance cell survival in vitro can ameliorate the symptoms of Huntington’s Disease – and beyond its neuroprotective effects, may even have disease modifying properties. They’ve published the first proof of concept in animals, aiming to bring the compound into human studies.

BioPharmaceutical Research & Development

Recent Tech Transfer Deals (01/08)

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

Deals Update (01/2008)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Medical Device
See All

Company Information

  • Industry
  • Academic and Research Institutions